Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVCNASDAQ:DTILNASDAQ:IKNANASDAQ:MDCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$0.98+7.2%$0.79$0.40▼$1.73$15.41M0.33338,913 shs205,087 shsDTILPrecision BioSciences$5.33-3.1%$5.05$3.61▼$13.44$56.23M1.59179,069 shs69,472 shsIKNAIkena Oncology$1.19-1.7%$1.27$0.97▼$1.94$57.43M0.48172,463 shs101,022 shsMDCXMedicus Pharma$3.95-0.3%$3.58$1.80▼$6.00$52.99MN/A51,653 shs81,510 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma+4.00%+6.55%+29.22%+73.99%-38.45%DTILPrecision BioSciences-3.17%+9.56%+8.06%+8.27%-43.99%IKNAIkena Oncology0.00%+9.01%-10.37%-19.33%-6.20%MDCXMedicus Pharma+1.02%-1.00%+23.36%+38.46%+395,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABVCABVC BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ADTILPrecision BioSciences3.8838 of 5 stars3.52.00.04.62.51.70.6IKNAIkena Oncology3.2991 of 5 stars3.35.00.00.03.21.71.3MDCXMedicus PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVCABVC BioPharma 0.00N/AN/AN/ADTILPrecision BioSciences 3.00Buy$37.67606.69% UpsideIKNAIkena Oncology 2.50Moderate Buy$3.00152.10% UpsideMDCXMedicus Pharma 3.50Strong Buy$12.00203.80% UpsideCurrent Analyst Ratings BreakdownLatest ABVC, IKNA, MDCX, and DTIL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/14/2025MDCXMedicus PharmaD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/14/2025MDCXMedicus PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.003/28/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.003/19/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.002/19/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVCABVC BioPharma$509.59K30.23N/AN/A$1.02 per share0.96DTILPrecision BioSciences$68.70M0.82N/AN/A$4.53 per share1.18IKNAIkena Oncology$659K87.14N/AN/A$3.52 per share0.34MDCXMedicus PharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVCABVC BioPharma-$10.52M-$0.47N/A∞N/A-1,619.65%-104.94%-56.81%N/ADTILPrecision BioSciences-$61.32M$1.9088.85N/AN/A11.48%-23.69%-6.98%5/12/2025 (Estimated)IKNAIkena Oncology-$68.17M-$1.01N/AN/AN/AN/A-36.88%-33.08%5/12/2025 (Estimated)MDCXMedicus PharmaN/AN/A0.00N/AN/AN/AN/AN/A6/27/2025 (Estimated)Latest ABVC, IKNA, MDCX, and DTIL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025DTILPrecision BioSciences-$0.38N/AN/AN/A$5.00 millionN/A5/12/2025Q1 2025IKNAIkena Oncology-$0.21N/AN/AN/AN/AN/A4/15/2025Q4 2024ABVCABVC BioPharmaN/A$0.04N/A$0.04N/AN/A3/28/2025Q4 2024MDCXMedicus Pharma-$0.32-$0.18+$0.14-$0.18N/AN/A3/26/2025Q4 2024DTILPrecision BioSciences-$2.09-$3.20-$1.11-$2.22$4.28 million$3.47 million3/11/2025Q4 2024IKNAIkena Oncology-$0.23-$0.18+$0.05-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVCABVC BioPharmaN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/AIKNAIkena OncologyN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVCABVC BioPharmaN/A0.340.34DTILPrecision BioSciences0.349.229.22IKNAIkena OncologyN/A15.3215.32MDCXMedicus PharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVCABVC BioPharma11.38%DTILPrecision BioSciences37.99%IKNAIkena Oncology75.00%MDCXMedicus PharmaN/AInsider OwnershipCompanyInsider OwnershipABVCABVC BioPharma11.90%DTILPrecision BioSciences4.00%IKNAIkena Oncology5.94%MDCXMedicus PharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVCABVC BioPharma3015.78 million11.43 millionNot OptionableDTILPrecision BioSciences20010.55 million7.36 millionNo DataIKNAIkena Oncology7048.26 million45.39 millionNot OptionableMDCXMedicus PharmaN/A13.42 millionN/AN/AABVC, IKNA, MDCX, and DTIL HeadlinesRecent News About These CompaniesMedicus Pharma (NASDAQ:MDCX) Receives "Buy" Rating from D. Boral CapitalApril 23 at 8:39 AM | marketbeat.comD. Boral Capital Reaffirms Buy Rating for Medicus Pharma (NASDAQ:MDCX)April 23 at 2:23 AM | americanbankingnews.comMedicus Pharma Expands Phase 2 Study for Basal Cell Carcinoma TreatmentApril 21, 2025 | tipranks.comMedicus Pharma expands basal cell carcinoma study after encouraging early dataApril 21, 2025 | proactiveinvestors.comMedicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)April 21, 2025 | newsfilecorp.comD. Boral Capital Initiates Coverage on Medicus Pharma (NASDAQ:MDCX)April 16, 2025 | americanbankingnews.comD. Boral Capital Initiates Coverage of Medicus Pharma (MDCX) with Buy RecommendationApril 14, 2025 | msn.comResearch Analysts Set Expectations for Medicus Pharma Q1 EarningsApril 12, 2025 | marketbeat.comValueTheMarkets Insights: While Big Pharma Stalls, One Small-Cap Breaks OutMarch 28, 2025 | wral.comMedicus Pharma Ltd. (MDCX)March 25, 2025 | finance.yahoo.comMedicus Pharma announces annual meeting dateMarch 22, 2025 | investing.comMedicus Pharma Secures $4.2 Million for Innovative Skin Treatment TrialsMarch 10, 2025 | tipranks.comMedicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A OfferingMarch 10, 2025 | newsfilecorp.comMedicus Pharma CEO discusses latest skin cancer trial results - ICYMIMarch 8, 2025 | proactiveinvestors.comMedicus Pharma unveils pricing of financing to advance skin cancer treatmentMarch 7, 2025 | proactiveinvestors.comMedicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A OfferingMarch 6, 2025 | newsfilecorp.comMedicus making its move with basal cell carcinoma candidateMarch 6, 2025 | thepharmaletter.comMedicus Pharma announces positively trending interim analysis for SKNJCT-003March 6, 2025 | markets.businessinsider.comMedicus Pharma reports over 60% complete clearance in Phase 2 BCC trial interim resultsMarch 6, 2025 | proactiveinvestors.comMedicus Pharma Ltd. Reports Positive Interim Results for Phase 2 Study on Non-Invasive Treatment of Basal Cell CarcinomaMarch 6, 2025 | quiverquant.comMedicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)March 6, 2025 | newsfilecorp.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABVC, IKNA, MDCX, and DTIL Company DescriptionsABVC BioPharma NASDAQ:ABVC$0.98 +0.07 (+7.19%) Closing price 04:00 PM EasternExtended Trading$0.96 -0.02 (-1.69%) As of 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.Precision BioSciences NASDAQ:DTIL$5.33 -0.17 (-3.09%) Closing price 04:00 PM EasternExtended Trading$5.23 -0.10 (-1.88%) As of 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Ikena Oncology NASDAQ:IKNA$1.19 -0.02 (-1.65%) Closing price 04:00 PM EasternExtended Trading$1.20 +0.01 (+0.42%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Medicus Pharma NASDAQ:MDCX$3.95 -0.01 (-0.25%) As of 03:59 PM EasternMedicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
